{"data":[{"accessionNo":"0000093751-26-000443","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001626971","issuerName":"CORVUS PHARMACEUTICALS INC","ticker":"CRVS","cusip":"221015100","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":4474091,"percentOfClass":5.3,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0002012383-26-002292","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001626971","issuerName":"CORVUS PHARMACEUTICALS INC","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":6325157,"percentOfClass":7.5,"filedAt":"2026-07-27","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000919574-26-003217","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Sirenia Capital Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":6831828,"percentOfClass":7.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000919574-26-003217","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Alex Silverstein","reportingCik":null,"personType":"HC,IN","sharesOwned":6831828,"percentOfClass":7.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000919574-26-003462","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000919574-26-003462","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000919574-26-003462","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0002012383-26-001739","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"CORVUS PHARMACEUTICALS INC","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":5387818,"percentOfClass":6.4,"filedAt":"2026-04-27","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000102909-26-001004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals Inc","ticker":"CRVS","cusip":"221015100","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-015263","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Richard A. Miller","reportingCik":null,"personType":"IN","sharesOwned":6085922,"percentOfClass":7.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-015263","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985","reportingCik":null,"personType":"OO","sharesOwned":1188103,"percentOfClass":1.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-015263","formType":"SCHEDULE 13G/A","amendmentNo":10,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Sandra J. Horning","reportingCik":null,"personType":"IN","sharesOwned":1188103,"percentOfClass":1.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street Partners, LLC","reportingCik":"0001193586","personType":"IA","sharesOwned":3275616,"percentOfClass":3.9,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2012 Direct Fund LP","reportingCik":"0001537362","personType":"PN","sharesOwned":715361,"percentOfClass":0.9,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2014 Direct Fund LP","reportingCik":"0001594043","personType":"PN","sharesOwned":736033,"percentOfClass":0.9,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2011 Direct Fund LP","reportingCik":"0001507788","personType":"PN","sharesOwned":694854,"percentOfClass":0.8,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2013 Direct Fund LP","reportingCik":"0001564720","personType":"PN","sharesOwned":541133,"percentOfClass":0.6,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street Venture/Growth Fund VI LP","reportingCik":"0001623687","personType":"PN","sharesOwned":236128,"percentOfClass":0.3,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2018 Direct Venture/Growth Fund LP","reportingCik":"0001720383","personType":"PN","sharesOwned":126806,"percentOfClass":0.2,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2016 Direct Venture/Growth Fund LP","reportingCik":"0001653592","personType":"PN","sharesOwned":67769,"percentOfClass":0.1,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2017 Direct Venture/Growth Fund LP","reportingCik":"0001685559","personType":"PN","sharesOwned":87668,"percentOfClass":0.1,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0001104659-26-010750","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-23","reportingPerson":"Adams Street 2015 Direct Venture/Growth Fund LP","reportingCik":"0001623365","personType":"PN","sharesOwned":69864,"percentOfClass":0.1,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000102909-26-000049","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001626971","issuerName":"Corvus Pharmaceuticals Inc","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":3873482,"percentOfClass":5.18,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000947871-26-000068","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001626971","issuerName":"CORVUS PHARMACEUTICALS, INC.","ticker":"CRVS","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2026-01-23","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":"0001055951","personType":"IA","sharesOwned":8609091,"percentOfClass":10.3,"filedAt":"2026-01-27","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0000947871-26-000068","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001626971","issuerName":"CORVUS PHARMACEUTICALS, INC.","ticker":"CRVS","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2026-01-23","reportingPerson":"ORBIMED CAPITAL GP V LLC","reportingCik":"0001615374","personType":"OO","sharesOwned":8609091,"percentOfClass":10.3,"filedAt":"2026-01-27","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"},{"accessionNo":"0002012383-25-002853","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001626971","issuerName":"CORVUS PHARMACEUTICALS INC","ticker":"CRVS","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":4015510,"percentOfClass":5.4,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/crvs"}],"updatedAt":"2026-11-05T12:02:06.165Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/crvs","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}